Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe
and tolerated in patients with primary and secondary hepato-pancreato-biliary and
gastrointestinal neoplasia as measured by exploring the maximum tolerated dose (MTD). At
level of MTD, additional patients will be included aimed for assessing the efficacy profile
in these neoplasia entities.